150
Participants
Start Date
November 19, 2020
Primary Completion Date
January 30, 2021
Study Completion Date
January 30, 2021
EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
"Federal State Budgetary Institution of Healthcare Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency (FGBUZ MSCH-163, FMBA of Russia)", Kol'tsovo
"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology Vector"
OTHER_GOV